MBP and myeloid sarcoma: Therapy was safe and tolerable and resulted in reduced frequency of T cells reactive with MBP. Clinically, there was a tendency for the treated group to have fewer exacerbations however a larger phase III clinical trial did not show statistically significant benefit in MS.